Literature DB >> 23860588

Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature.

A Chiò1, G Logroscino, B J Traynor, J Collins, J C Simeone, L A Goldstein, L A White.   

Abstract

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is relatively rare, yet the economic and social burden is substantial. Having accurate incidence and prevalence estimates would facilitate efficient allocation of healthcare resources.
OBJECTIVE: To provide a comprehensive and critical review of the epidemiological literature on ALS.
METHODS: MEDLINE and EMBASE (1995-2011) databases of population-based studies on ALS incidence and prevalence reporting quantitative data were analyzed. Data extracted included study location and time, design and data sources, case ascertainment methods and incidence and/or prevalence rates. Medians and interquartile ranges (IQRs) were calculated, and ALS case estimates were derived using 2010 population estimates.
RESULTS: In all, 37 articles met the inclusion criteria. In Europe, the median incidence rate (/100,000 population) was 2.08 (IQR 1.47-2.43), corresponding to an estimated 15,355 (10,852-17,938) cases. Median prevalence (/100,000 population) was 5.40 (IQR 4.06-7.89), or 39,863 (29,971-58,244) prevalent cases.
CONCLUSIONS: Disparity in rates among ALS incidence and prevalence studies may be due to differences in study design or true variations in population demographics such as age and geography, including environmental factors and genetic predisposition. Additional large-scale studies that use standardized case ascertainment methods are needed to more accurately assess the true global burden of ALS.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23860588      PMCID: PMC4049265          DOI: 10.1159/000351153

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  78 in total

1.  Incidence of amyotrophic lateral sclerosis in Sicily: A population based study.

Authors:  Paolo Ragonese; Eleonora Cellura; Paolo Aridon; Marco D'amelio; Rossella Spataro; Alfonsa Claudia Taiello; Davide Maimone; Vincenzo La Bella; Giovanni Savettieri
Journal:  Amyotroph Lateral Scler       Date:  2012-03-13

2.  Prevalence of amyotrophic lateral sclerosis in Texas, 1998-2003.

Authors:  Laurie Wagner; Natalie P Archer; Dhelia M Williamson; Judith P Henry; Randolph Schiffer; Carlayne E Jackson
Journal:  Tex Med       Date:  2012-05-01

3.  Changing incidence and subtypes of ALS in Modena, Italy: A 10-years prospective study.

Authors:  Eleni Georgoulopoulou; Marco Vinceti; Francesca Bonvicini; Patrizia Sola; Carlo Alberto Goldoni; Gianfranco De Girolamo; Diana Ferraro; Paolo Nichelli; Jessica Mandrioli
Journal:  Amyotroph Lateral Scler       Date:  2011-07-06

4.  The National Amyotrophic Lateral Sclerosis (ALS) Registry.

Authors:  Vinicius C Antao; D Kevin Horton
Journal:  J Environ Health       Date:  2012 Jul-Aug       Impact factor: 1.179

5.  Incidence of amyotrophic lateral sclerosis in the Faroe Islands.

Authors:  P Joensen
Journal:  Acta Neurol Scand       Date:  2011-10-29       Impact factor: 3.209

6.  Clinical epidemiology of ALS in Liguria, Italy.

Authors:  Monica Bandettini di Poggio; Maria Pia Sormani; Romina Truffelli; Paola Mandich; Paola Origone; Simonetta Verdiani; Vittorio Mantero; Carlo Scialò; Angelo Schenone; Giovanni Luigi Mancardi; Claudia Caponnetto
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2012-10-03       Impact factor: 4.092

7.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

8.  An increase in ALS incidence on the Kii Peninsula, 1960-2009: a possible link to change in drinking water source.

Authors:  Tameko Kihira; Sohei Yoshida; Tetsuya Kondo; Keiko Iwai; Sachiko Wada; Satomi Morinaga; Yoshinori Kazimoto; Tomoyoshi Kondo; Kazusi Okamoto; Yasumasa Kokubo; Shigeki Kuzuhara
Journal:  Amyotroph Lateral Scler       Date:  2012-06

9.  Chromosome 9 ALS and FTD locus is probably derived from a single founder.

Authors:  Kin Mok; Bryan J Traynor; Jennifer Schymick; Pentti J Tienari; Hannu Laaksovirta; Terhi Peuralinna; Liisa Myllykangas; Adriano Chiò; Aleksey Shatunov; Bradley F Boeve; Adam L Boxer; Mariely DeJesus-Hernandez; Ian R Mackenzie; Adrian Waite; Nigel Williams; Huw R Morris; Javier Simón-Sánchez; John C van Swieten; Peter Heutink; Gabriella Restagno; Gabriele Mora; Karen E Morrison; Pamela J Shaw; Pamela Sara Rollinson; Ammar Al-Chalabi; Rosa Rademakers; Stuart Pickering-Brown; Richard W Orrell; Michael A Nalls; John Hardy
Journal:  Neurobiol Aging       Date:  2011-09-16       Impact factor: 4.673

10.  Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study.

Authors:  Elisa Majounie; Alan E Renton; Kin Mok; Elise G P Dopper; Adrian Waite; Sara Rollinson; Adriano Chiò; Gabriella Restagno; Nayia Nicolaou; Javier Simon-Sanchez; John C van Swieten; Yevgeniya Abramzon; Janel O Johnson; Michael Sendtner; Roger Pamphlett; Richard W Orrell; Simon Mead; Katie C Sidle; Henry Houlden; Jonathan D Rohrer; Karen E Morrison; Hardev Pall; Kevin Talbot; Olaf Ansorge; Dena G Hernandez; Sampath Arepalli; Mario Sabatelli; Gabriele Mora; Massimo Corbo; Fabio Giannini; Andrea Calvo; Elisabet Englund; Giuseppe Borghero; Gian Luca Floris; Anne M Remes; Hannu Laaksovirta; Leo McCluskey; John Q Trojanowski; Vivianna M Van Deerlin; Gerard D Schellenberg; Michael A Nalls; Vivian E Drory; Chin-Song Lu; Tu-Hsueh Yeh; Hiroyuki Ishiura; Yuji Takahashi; Shoji Tsuji; Isabelle Le Ber; Alexis Brice; Carsten Drepper; Nigel Williams; Janine Kirby; Pamela Shaw; John Hardy; Pentti J Tienari; Peter Heutink; Huw R Morris; Stuart Pickering-Brown; Bryan J Traynor
Journal:  Lancet Neurol       Date:  2012-03-09       Impact factor: 44.182

View more
  193 in total

Review 1.  Immune-mediated processes in neurodegeneration: where do we stand?

Authors:  Marc Fakhoury
Journal:  J Neurol       Date:  2016-02-12       Impact factor: 4.849

Review 2.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

3.  Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.

Authors:  Alessandra Gaiani; Ilaria Martinelli; Luca Bello; Giorgia Querin; Marco Puthenparampil; Susanna Ruggero; Elisabetta Toffanin; Annachiara Cagnin; Chiara Briani; Elena Pegoraro; Gianni Sorarù
Journal:  JAMA Neurol       Date:  2017-05-01       Impact factor: 18.302

Review 4.  Amyotrophic lateral sclerosis: cell vulnerability or system vulnerability?

Authors:  Kevin Talbot
Journal:  J Anat       Date:  2013-09-08       Impact factor: 2.610

5.  Meta-analytic evaluation of the association between head injury and risk of amyotrophic lateral sclerosis.

Authors:  Yukari Watanabe; Takamitsu Watanabe
Journal:  Eur J Epidemiol       Date:  2017-10-27       Impact factor: 8.082

6.  The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS.

Authors:  Ravinder Malik; Helen Meng; Piriya Wongkongkathep; Christian I Corrales; Niki Sepanj; Ryan S Atlasi; Frank-Gerrit Klärner; Thomas Schrader; Melissa J Spencer; Joseph A Loo; Martina Wiedau; Gal Bitan
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

7.  Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany.

Authors:  Angela Rosenbohm; Mingsheng Liu; Gabriele Nagel; Raphael S Peter; Bo Cui; Xiaoguang Li; Jan Kassubek; Dietrich Rothenbacher; Dorothée Lulé; Liying Cui; Albert C Ludolph
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

Review 8.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

9.  Depression and wish to die in a multicenter cohort of ALS patients.

Authors:  Judith G Rabkin; Raymond Goetz; Pam Factor-Litvak; Jonathan Hupf; Martin McElhiney; Jessica Singleton; Hiroshi Mitsumoto
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-12-08       Impact factor: 4.092

Review 10.  Amyotrophic Lateral Sclerosis: Current Status in Diagnostic Biomarkers.

Authors:  Katerina Kadena; Panayiotis Vlamos
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.